Financial toxicity is prevalent among hepatopancreatobiliary cancer patients

An analysis of the National Health Interview Survey highlights significant financial toxicity among U.S. patients with hepatopancreatobiliary (HPB) cancers. Of 5.6 million adults, 10.1% delayed medical care due to cost, while 8.4% could not afford necessary treatment. Uninsured patients faced markedly higher odds of financial challenges, and non-white patients were also more likely to delay care. The findings suggest urgent need for targeted interventions to reduce financial burdens impacting patient care in this population.